The company states: “Reported and organic revenue growth for the fourth quarter is expected to be approximately 6% and 4%, respectively, as compared to the same period a year ago. This is expected to result in fourth quarter revenue of approximately $772 million. For the full year 2025, reported and organic revenue growth is expected to be approximately 4% and 3%, respectively, as compared to the same period a year ago. This is expected to result in full year 2025 revenue of approximately $2,855 million. As previously announced, Prahlad Singh, will present at 9:45 a.m. PT tomorrow (January 13, 2026) at the 44th annual J.P. Morgan Healthcare Conference.”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVTY:
- The Week That Was, The Week Ahead: Macro and Markets, Jan. 11
- Revvity announces collaboration with Eli Lilly on AI drug discovery models
- Revvity price target raised to $112 from $108 at Evercore ISI
- OpenAI spoke to Revvity about licensing data, The Information reports
- Revvity price target raised to $107 from $102 at Wells Fargo